Charles Schwab Investment Management Inc. Has $5.97 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Charles Schwab Investment Management Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 665,087 shares of the biotechnology company’s stock after selling 78,963 shares during the period. Charles Schwab Investment Management Inc. owned 0.46% of Aurinia Pharmaceuticals worth $5,972,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aurinia Pharmaceuticals in the third quarter valued at approximately $3,330,000. Intech Investment Management LLC bought a new position in shares of Aurinia Pharmaceuticals in the 3rd quarter worth $262,000. FMR LLC grew its position in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,919 shares during the period. BNP Paribas Financial Markets increased its stake in Aurinia Pharmaceuticals by 172.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 20,324 shares in the last quarter. Finally, Verition Fund Management LLC raised its holdings in Aurinia Pharmaceuticals by 209.0% during the third quarter. Verition Fund Management LLC now owns 58,518 shares of the biotechnology company’s stock worth $429,000 after buying an additional 39,583 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Insider Activity at Aurinia Pharmaceuticals

In related news, insider Greg Keenan sold 8,305 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the sale, the insider now directly owns 153,484 shares of the company’s stock, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the transaction, the chief executive officer now directly owns 1,953,892 shares in the company, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Stock Up 1.1 %

AUPH stock opened at $8.53 on Tuesday. The firm has a market capitalization of $1.17 billion, a PE ratio of -56.86 and a beta of 1.26. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock’s 50 day moving average is $8.03 and its 200-day moving average is $8.01.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.